Method of producing catalytic antibodies (options), antigens for immunization, and the nucleotide sequence

 

The invention relates to the production potential of drugs aimed at the destruction of protein antigens, in particular glycoprotein gp 120 of the main surface protein of the human immunodeficiency virus. Catalytic antibodies are obtained from animals with spontaneous and induced autoimmune pathologies by introducing them fused protein consisting of the basic protein of myelin (fragments) and the potential of the substrate catalytic antibody (fragment), or a phosphate derivative of a peptide with the amino acid sequence Leu-Ala-Glu-Glu-Glu-Val. 5 C. and 4 h.p. f-crystals, 13 ill.

Description text in facsimile form (see graphic material)

Claims

1. Method of producing catalytic antibodies using animals with spontaneous and induced autoimmune pathologies, characterized in that as animals injected antigen protein consisting of the basic protein of myelin or its fragments and the potential of the substrate of the catalytic antibody or fragment potential of the substrate.

2. The method according to p. 1, characterized in that the potential of the substrate is gp 120 (power is ve animals with spontaneous and induced autoimmune pathologies using mice.

4. The method according to any of paragraphs.1-3, characterized in that use mice those lines for which immunization basic myelin protein or its fragments can cause the development of experimental autoimmune encephalomyelitis.

5. Protein having the amino acid sequence of SEQ ID No. 1 for catalytic antibodies by the method according to any of paragraphs.1-4.

6. The nucleotide sequence of SEQ ID No. 2, and encoding a protein having the amino acid sequence of SEQ ID No. 1.

7. Method of producing catalytic antibodies using animals with spontaneous and induced autoimmune pathologies, including the introduction of animals as antigen phosphate derived peptide fragment potential gp substrate 120, wherein the peptide has the amino acid sequence Leu-Ala-Glu-Glu-Glu-Val.

8. The method according to p. 7, characterized in that as autoimmune animal use mice predominantly line MRL-Ipr/Ipr.

9. Conjugate composition of:

Leu-Ala-Glu-Glu-Glu-ValR-(Oph)2for producing catalytic antibodies.

 

Same patents:

The invention relates to medicine, in particular to the treatment and pulmonology, and for the treatment of acute lung injury and fibrosis

The invention relates to the field of biotechnology, in particular to bioengineered product for ant Richter and method of manufacturing such a product

The invention relates to the field of immunobiotechnology and medicine and relates to monoclonal antibodies (MCAT) to SD person

v-integrins (options), receive (options) and use hybridoma, polypeptide, dna" target="_blank">

The invention relates to immunobiotechnology and applies to new monoclonal antibodies, methods for their production using hybridoma technology and our-integrin or vitronectin as antigens, polypeptides, representing light and heavy chains of the antibody and DNA encoding these polypeptides

The invention relates to medicine, in particular for the diagnosis of metabolic bone diseases

The invention relates to medical biotechnology and is concerned with the obtaining of monoclonal antibodies (MAB) and its fragments using hybridoma FERM BR-4382, which produces the above-mentioned antibody

The invention relates to the field of biotechnology and can be used in the biomedical industry with the aim of obtaining protein angiogenesis factor (chimeric protein angiogenin person)

The invention relates to the field of cell biology and Biophysics and can be used in the practice of medicine and pharmacology

The invention relates to genetic engineering, and in particular to means of gene therapy

The invention relates to medicine and biotechnology and the human semaphorin L (H-Sema-L) and the corresponding semaphorins in other types

The invention relates to genetic engineering, specifically to genes of receptors tyrosinekinase, and can be used to diagnose

The invention relates to the field of medicine and biotechnology and relates to immunogenic compositions containing the chimeric polypeptide of HIV, method of induction of an immune response to VIC and VIC/2, chimeric polypeptide VIC and VIC/2, a DNA molecule that encodes a chimeric polypeptide, the plasmid vector for expression of a chimeric polypeptide, polyclonal antibodies to VIC or VIC/2 and diagnostic test systems for the detection of antibodies to VIC and VIC

The invention relates to medicine and concerns НСV immunoreactive polypeptide compositions
Up!